The price of Cidara Therapeutics Inc (NASDAQ:CDTX) shares last traded on Wall Street rose 1.90% to $48.78.
CDTX stock price is now 79.64% away from the 50-day moving average and 136.16% away from the 200-day moving average. The market capitalization of the company currently stands at $1.08B.
On March 12, 2025, Citizens JMP recently initiated its ‘Mkt Outperform’ rating on the stock quoting a target price of $46, while ‘Cantor Fitzgerald’ rates the stock as ‘Overweight’
In other news, RA CAPITAL MANAGEMENT, L.P., Director bought 2,272,727 shares of the company’s stock on Jun 26 ’25. The stock was bought for $99,999,988 at an average price of $44.00. Upon completion of the transaction, the Director now directly owns 3,365,523 shares in the company, valued at $164.17 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 02 ’25, Director Mineo Chrysa bought 2,270 shares of the business’s stock. A total of $49,281 was incurred on buying the stock at an average price of $21.71. This leaves the insider owning 2,270 shares of the company worth $0.11 million. A total of 40.83% of the company’s stock is owned by insiders.
During the past 12 months, Cidara Therapeutics Inc has had a low of $10.14 and a high of $56.83. As of last week, the company has a debt-to-equity ratio of 0.02, a current ratio of 3.87, and a quick ratio of 3.87. The fifty day moving average price for CDTX is $27.1538 and a two-hundred day moving average price translates $20.6554 for the stock.
The latest earnings results from Cidara Therapeutics Inc (NASDAQ: CDTX) was released for 2025-03-31. The net profit margin was -59994.04% and return on equity was -299.58% for CDTX.
